Is Gland Pharma overvalued or undervalued?

As of 31 October 2025, Gland Pharma's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its valuation outlook. The company is currently considered overvalued. Key ratios include a PE ratio of 41.24, an EV to EBITDA of 21.51, and a Price to Book Value of 3.47, all of which are significantly higher than many peers in the industry.
In comparison to its peers, Gland Pharma's PE ratio is notably higher than Sun Pharma's 35.35 and much higher than Cipla's attractive PE of 22.29. This suggests that Gland Pharma's stock is priced at a premium relative to its competitors. Despite a recent YTD return of 7.79%, which slightly outperformed the Sensex's 7.42%, the overall valuation metrics indicate that Gland Pharma remains overvalued in the current market environment.